MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Geron Corp

Closed

SectorHealthcare

1.58 7.48

Overview

Share price change

24h

Current

Min

1.48

Max

1.61

Key metrics

By Trading Economics

Income

1.1M

-25M

Sales

19M

48M

EPS

-0.036

Profit margin

-53.331

Employees

229

EBITDA

12M

-16M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+204.05% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-684M

1.1B

Previous open

-5.9

Previous close

1.58

News Sentiment

By Acuity

79%

21%

363 / 386 Ranking in Healthcare

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 cze 2024, 10:19 UTC

Major Market Movers

Geron Shares Rise Premarket on FDA Nod for Rytelo

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

204.05% upside

12 Months Forecast

Average 4.5 USD  204.05%

High 7 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Sentiment

By Acuity

363 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.